Medical Ventures Corp.

Medical Ventures Corp.

May 16, 2006 14:00 ET

Medical Ventures to Showcase Metricath Product at Paris Conference

RICHMOND, BRITISH COLUMBIA--(CCNMatthews - May 16, 2006) - MEDICAL VENTURES CORP. (TSX VENTURE:MEV), a medical device company that specializes in developing products for the cardiovascular and surgical markets, is pleased to be showcasing its patented Metricath® catheter technology at EuroPCR06, a leading industry conference and tradeshow in Paris, France, from May 16 - 19.

EuroPCR, or The Paris Course on Revascularization, is an annual gathering of interventional cardiologists, radiologists and vascular surgeons from around the world. The event provides leading physicians in the field with an opportunity to discuss the latest techniques and technologies related to the treatment of heart and vascular diseases. More than 10,000 delegates attended in 2005.

The company will use its attendance at the forum to increase awareness of its patented Metricath technology, which allows interventional cardiologists, radiologists and vascular surgeons to make key measurements during angioplasty procedures. The Metricath System, which consists of a compact console and disposable balloon-tipped catheters, allows physicians to precisely measure arterial size and assess the correct placement of "stents" (expandable metallic tubes physicians implant into damaged vessels to improve and maintain proper blood flow).

"We are thrilled to once again be part of this very important gathering," said Paul Geyer, Medical Ventures' President and CEO. "EuroPCR is a key event for us to ensure physicians from North America, Europe, and around the world have the opportunity to learn about our developing product suite and in particular, the proven clinical benefits of our Metricath Gemini® catheter product."

The Gemini is the company's new, dual-balloon catheter that combines the Metricath's measurement technology with the treatment capability of a high-pressure angioplasty balloon. The Gemini provides doctors with the ability to both measure and treat damaged vessels using a single, cost-effective catheter.

Also meeting at EuroPCR will be the lead investigators for Medical Ventures' Gemini Angioplasty and Arterial Measurement Evaluation (GAAME) clinical trial. The trial, currently underway at research sites in the U.S. and the Netherlands, assesses the safety and effectiveness of using the Gemini product to treat diseased coronary arteries. Data from the trial will support the company's application for approval from the U.S. Food and Drug Administration (FDA) to use the Gemini in coronary arteries. The product is currently FDA cleared for use in peripheral applications.

Medical Ventures Corp. is a medical device company dedicated to developing technologies that address clinical needs in the quickly growing cardiovascular and surgical marketplace. MEV products help doctors treat a wide range of health concerns, including cardiovascular disease, stroke, hernias and obesity. The Company develops and manufactures the patented Metricath System catheter technology and PeriPatch™, a range of surgical tissue products. For more information please visit

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates", "believes", "may", "continues", "estimates", "expects", and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information